Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07065903 · ClinicalTrials.gov registry record
Nimodipine Variability in SAH
A clinical trial of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage, sponsored by University of Alberta.
- Recruiting
- Registry status
- 500
- Enrollment target
- 3
- Study locations
NCT07065903: Recruiting study of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage, sponsored by University of Alberta.
NCT07065903 is a study of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage that is actively recruiting participants, run by University of Alberta. The registered enrollment target is 500 participants, above the 101-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (395% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07065903, a study of Subarachnoid Hemorrhage, Aneurysmal and Subarachnoid Aneurysm Hemorrhage, is actively recruiting participants, sponsored by University of Alberta.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 3
- Study locations
Study Summary
Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patients during their most productive years. Complications following SAH are common, and they can cause major long-term disability. Only one medication - nimodipine - has been proven to benefit the health and wellbeing of these patients. All SAH patients should receive nimodipine for 21 days at a fixed dose. However, our early work suggested that all patients are not getting equal amounts of nimodipine into their blood. In addition, the two different forms (structural mirror images) of nimodipine might have different effects. Reduced amounts of nimodipine in the blood may lessen its benefit and contribute to worsening health and wellbeing of SAH patients. The overall goal of this research is to see what happens with different nimodipine doses and to confirm whether the two forms of nimodipine have different effects. The investigators will conduct a multi-centre study in adult patients admitted for SAH in Canada and the USA. The investigators will collect blood samples to determine the amount of each type of nimodipine in each participant's body, and then will check to see how each participant is doing at 90 days following SAH. They will also check other factors affecting nimodipine levels, so that they can in the future suggest dose recommendations that are actually tailored to each patient.
Primary Outcome
The mRS is a measure of disability ranging from 0 (no symptoms) to 6 (death) and is the recommended functional outcome scale in studies involving SAH patients.
Conditions Studied
Study Locations (3)
Virginia
- VCU Medical Center - Richmond
Alberta
- University of Alberta Hospital - Edmonton
Ontario
- University Health Network - Toronto Western Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-05-13 |
| Est. Completion | 2029-09 |
What NCT07065903 shows while recruiting
NCT07065903 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 101-participant average among 8 other Subarachnoid Hemorrhage, Aneurysmal trials with a reported enrollment target (395% higher).
The record links to 2 conditions, with Subarachnoid Hemorrhage, Aneurysmal appearing as the primary indexed condition, and to 0 interventions.
NCT07065903 reports a single indexed study location in Virginia, Alberta, Ontario.
Frequently Asked Questions
What is clinical trial NCT07065903 about?
NCT07065903 is a clinical study titled "Nimodipine Variability in SAH". Aneurysmal subarachnoid hemorrhage (SAH) is a life-threatening neurological illness: it is bleeding in the brain after a bulging blood vessel (a brain aneurysm) ruptures. Although SAH accounts for only 5% of all strokes, it often happens in middle age and it puts a significant burden on many patient...
What is the current status of trial NCT07065903?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-05-13. Estimated completion is 2029-09.
What conditions does trial NCT07065903 study?
This clinical trial studies the following conditions: Subarachnoid Hemorrhage, Aneurysmal, Subarachnoid Aneurysm Hemorrhage.
Who is sponsoring clinical trial NCT07065903?
This trial is sponsored by University of Alberta, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07065903 being conducted?
This trial has 3 study locations across Virginia, Alberta, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subarachnoid Hemorrhage, Aneurysmal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07065903's enrollment target sits among peer trials
500 2nd of 8 the highest of 8 other Subarachnoid Hemorrhage, Aneurysmal trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Subarachnoid Hemorrhage, Aneurysmal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Feasibility, and Efficacy of Non-invasive Vagus Nerve Stimulation (nVNS) in the Treatment of Aneurysmal Subarachnoid Hemorrhage
RECRUITING · NA
-
Telavancin Blood and Cerebrospinal Fluid Concentrations in Patients With External Ventricular Drainage
RECRUITING · Phase 4
-
Infusion of Lidocaine and Steroids in Middle Meningeal Artery for Pain in Subarachnoid Hemorrhage
RECRUITING · Phase 2
-
Effects of Head-of-Bed on Intracranial Pressure
RECRUITING · NA
-
Augmented Renal Clearance in Neurocritical Care
RECRUITING
-
BLOCK-SAH - PPF-Block for Post-SAH Headache
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI